Zach Taiji's Wiki

Company Mentions:
- LEO Pharma is fined $10k USD for violating the Swedish pharmaceutical industry’s ethical guidelines for marketing medicines, after including promotional material for Adtralza in a commercial video. (MedWatch)
- LEO Pharma’s Brian Hilberdink is interviewed on the Medical Marketing and Media Podcast to discuss upcoming launches in the eczema space.
tralokinumab (ADBRY):
- A poster from the 2024 Elevate-Derm West Conference reports the safety and efficacy of ADBRY in patients with AD affecting the genitals. (X, Dermatology Times)
- In a Reddit thread discussing switching from DUPIXENT to ADBRY, most patients report minimal side effects and positive results.
delgocitinib (Anzupgo):
- Switzerland approves Anzupgo for adults with moderate to severe CHE, supported by the recent DELTA 1, 2, and 3 trials. (Dermatology Times, The Pharma Letter, Press Release, Dermatology Digest)
- Christopher Bunick, MD, PhD, discusses the multifactorial nature of CHE, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways. (Dermatology times)

The National Eczema Association publishes a 2024 Eczema treatment roundup, mentioning the approvals of ZORYVE and EBGLYSS earlier this year. Upcoming approvals are also noted, including delgocitinib, Nemluvio, and VTAMA.
Glamour awards ZORYVE with its 2024 Health and Wellness award for the Best Eczema Product.
Concerto Biosciences doses its first participant in a Phase 1 trial of ENS-002, a microbiome-based therapy for AD. (Dermatology Times, Clinical Trials Arena)
A poster presented at the SPDA fall dermatology conference finds that dupilumab combined with topical corticosteroids shows superior efficacy over lebrikizumab in improving the QOL and clinical outcomes in AD. (Dermatology Times)
Upadacitinib is found to be mostly safe and effective for up to 76 weeks for adolescents with AD. (Healio)
The Pharma Letter provides an overview of current and future JkAK inhibitor-based treatments for AD.
The Canada’s Drug Agency recommends that EBGLYSS not be not be reimbursed by public drug plans; Eli Lilly Canada responds in disappointment. (TipRanks)
Rapt Therapeutics stops the development of zelnecirnon for the treatment of AD and asthma. (MarketWatch)
The Severe Atopic Dermatitis Association (SADA) and the Danish Embassy are advocating for the Korean government to allow cross-dosing of biologics and JAK inhibitors for severe AD patients. (Korea Biomedical Review)
A study in Japan highlights the sustained long-term efficacy of dupilumab in treating AD. (HCP Live)

Dr. Reddy’s Laboratories

Company Mentions:
- Dr. Reddy’s recalls 2,040 bottles of morphine sulfate extended-release tablets for failing to meet impurity/degradation specifications, after a report by the FDA. (Pharmacy Learning Network)
denosumab:
- An article in MedScape about stopping bone loss after the discontinuation of denosumab underlines the importance of proactive shared decision-making, long-term adherence strategies, and further research to identify optimal sequential therapies.
- A new study finds that denosumab raises hypocalcemia risk in patients with chronic kidney disease. (MedScape)
- Celltrion presents additional data from its phase III trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) at ACR Convergence 2024. (Press release) Today, South Korea’s Ministry of Food and Drug Safety (MFDS) approved CT-41. (BioWorld)
- Samsung Bioepis receives an endorsement from the European Medicines Agency (EMA) for its denosumab biosimilars. (CiteLine)

Company Mentions:
- Paratek completes the onshoring of US-based manufacturing for NUZYRA, making it the only novel antibiotic with a domestic supply chain. (Press release, Medical Countermeasures/BARDA)
omadacycline (NUZYRA):
- In a Phase IIb study of 66 adult patients with NTM-PD caused by MABc, 34.1% of patients treated with omadacycline saw an improvement in at least 50% of their NTM symptoms present at baseline. in patients with NTM, showing at least 50% improvement in patients. (Clinical Trials Arena, GlobalData)